Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$148.85

5.27 (3.67%)

, ARIA

Acquired by TKPYY 2/17

$23.75

10.01 (72.85%)

08:11
01/10/17
01/10
08:11
01/10/17
08:11

ARIAD acquisition supports potential takeout premium for TESARO, says Leerink

Leerink analyst Seamus Fernandez says the acquisition of ARIAD (ARIA) by Takeda (TKPYY) for $24 per share appears to be relatively in-line with other commercial stage acquisitions, and supports a potential acquisition price for TESARO (TSRO) of greater than $170 per share based on consensus forecasts. While TESARO remains well positioned to grow independently, the analyst believes a validated PARP inhibitor like niraparib could offer a durable and strategically important product opportunity for multiple suitors. He reiterates an Outperform rating on TESARO's shares.

TSRO

Tesaro

$148.85

5.27 (3.67%)

ARIA

Acquired by TKPYY 2/17

$23.75

10.01 (72.85%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$21.72

0.33 (1.54%)

  • 11

    Jan

  • 11

    Jan

  • 11

    Jan

  • 21

    Feb

  • 29

    Apr

  • 30

    Jun

TSRO Tesaro
$148.85

5.27 (3.67%)

12/21/16
JANY
12/21/16
NO CHANGE
Target $44
JANY
Neutral
Clovis price target raised to $44 from $38 at Janney Capital
Janney Capital analyst Debjit Chattopadhyay raised his price target for Clovis Oncology to $44 to reflect his assumption of $36M in Rubraca sales for FY17. Clovis is launching Rubraca in the U.S. with around 85 sales reps, and the analyst assumes a similar sized organization in the major European markets. He assumes Clovis launches the drug without a partner in Europe. He believes the FDA's position on competitor TESARO's (TSRO) niraparib will have implications for Clovis prior to the ARIEL3 data. Chattopadhyay keeps a Neutral rating on Clovis. The stock is up 8% to $45.86 in midday trading.
01/09/17
LEER
01/09/17
NO CHANGE
Target $152
LEER
Outperform
TESARO price target raised to $152 from $115 at Leerink
Leerink analyst Seamus Fernandez raised his price target for TESARO to $152 from $115 to fully incorporate his high expectations for a broad label and reflect niraparib's transformation to a commercial stage asset. The analyst notes that the "strong data" from niraparib's NOVA trial, along with the lack of an expected FDA panel, should result in a broad label in the second-line or greater ovarian cancer maintenance setting, while ongoing niraparib trials in breast cancer and front-line ovarian cancer maintenance and the company's IO platform should be additional potential drivers of upside for the stock. Fernandez sees TESARO as an "attractive takeout target," and reiterates an Outperform rating on the shares.
01/04/17
GABE
01/04/17
NO CHANGE
GABE
Gabelli sees Incyte as more likely target following Gilead hire
Gilead (GILD) is more likely to buy Incyte (INCY) after naming Alessandro Riva to head its Hematology and Oncology Therapeutic unit, Gabelli analyst Jing He tells investors in a research note. Dr. Riva is a Novartis (NVS) veteran while Incyte is led by a team of Novartis veterans and has collaborated with Novartis Oncology on its key drug, Jakafi, the analyst points out. He believes Incyte is "big enough to move the needle" and bring long term growth to Gilead. The analyst lists Seattle Genetics (SGEN) and TESARO (TSRO) as other potential targets for the biotech giant. He believes Incyte is the "best fit."
12/27/16
FBRC
12/27/16
NO CHANGE
Target $151
FBRC
Outperform
FBR Capital ups TESARO price target to $151
FBR Capital analyst Ed White raised his price target for TESARO to $151 from $133 and keeps the Outperform rating on the shares. The oncology-focused biopharmaceutical company closed Friday up $7.27 to $139.86. TESARO recently announced that the FDA has granted Priority Review for niraparib with a June 30, 2017 action date, White tells investors in a research note. He believes niraparib could be a potential blockbuster PARP inhibitor. Meanwhile, the launch of Varubi continues to "ramp up," with sequential quarter-over-quarter unit growth of 14%, the analyst writes. White says the drug achieved a 28% share of the oral NK-1 market in the U.S. in September.
ARIA Acquired by TKPYY 2/17
$23.75

10.01 (72.85%)

12/01/16
WBLR
12/01/16
NO CHANGE
WBLR
Celgene, Zoetis among top healthcare picks at William Blair
William Blair analysts named their top health care picks for 2017, identifying Evolent Health (EVH) as their top HC Services and HC IT pick, Zoetis (ZTS) as their top dental and animal health pick,and Pacific Biosciences (PACB) as their top diagnostic services and life sciences choice, The firm identified ARIAD (ARIA), Celgene (CELG) and SAGE Therapeutics (SAGE) as their top biotech choices. It named Edwards Lifesciences (EW), Nevro (NVRO), and K2M Group (KTWO) as its favorite med tech picks.
11/03/16
11/03/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BioMarin (BMRN) initiated with a Buy at Deutsche Bank. 2. Ambev (ABEV) reinstated with an Equal Weight at Barclays. 3. ARIAD (ARIA) initiated with a Hold at Deutsche Bank. 4. Thomson Reuters (TRI) reinstated with a Neutral at JPMorgan. 5. Exelixis (EXEL) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage click here.
01/10/17
LEHM
01/10/17
UPGRADE
Target $24
LEHM
Equal Weight
ARIAD upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Paul Choi upgraded ARIAD Pharmaceuticals to Equal Weight saying the all cash acquisition by Takeda is a positive outcome for shareholders. The analyst assumes the deal closes with no competing bids and upped his price target for the shares to $24 from $9.
01/10/17
JEFF
01/10/17
DOWNGRADE
Target $24
JEFF
Hold
ARIAD downgraded to Hold from Buy at Jefferies
Jefferies analyst Eun Yang downgraded ARIAD Pharmaceuticals to Hold on expectations the Takeda acquisition will close by the end of February. The analyst views the deal as a "nice surprise at a significant premium." She raised her price target for the shares to $24 from $11.
TKPYY Takeda Pharmaceutical Co. Ltd.
$21.72

0.33 (1.54%)

06/08/16
RHCO
06/08/16
NO CHANGE
RHCO
Ultragenyx collaboration with Takeda 'exceptionally positive,' says SunTrust
After Ultragenyx (RARE) announced a development and commercialization collaboration for rare genetic diseases with Takeda (TKPYY), SunTrust says the deal terms are "exceptionally positive" for Ultragenyx. The firm notes that the latter company will receive both compounds and cash payments from Takeda, while Takeda will only get comemrcial rights in Asia. The firm keeps a Buy rating on Ultragenyx.
09/15/16
WELS
09/15/16
NO CHANGE
WELS
Street underestimating potential of PRA Health deal, says Wells Fargo
Wells Fargo believes that the Street is underestimating the potential benefit to PRA Health (PRAH) of its deal with Takeda (TKPYY). The firm expects PRA's bookings over the next year to significantly exceed the industry average, causing 2017 and 2018 consensus estimates for the company to rise. Wells raised its price target on PRA to $65-$67 from $56-$59 and keeps an Outperform rating on the shares.
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.
07/07/16
UBSW
07/07/16
INITIATION
UBSW
Neutral
Takeda Pharmaceutical initiated with a Neutral at UBS
UBS analyst Atsushi Seki started Takeda with a Neutral rating and Y4,600 price target.

TODAY'S FREE FLY STORIES

GM

General Motors

$38.99

0.29 (0.75%)

12:25
09/20/17
09/20
12:25
09/20/17
12:25
Periodicals
GM and striking workers union Unifor in informal talks, Automotive News says »

General Motors and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:21
09/20/17
09/20
12:21
09/20/17
12:21
Hot Stocks
Ackman says ADP CEO's stake lot more levered than Pershing's »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:20
09/20/17
09/20
12:20
09/20/17
12:20
Hot Stocks
Ackman says ADP stock options owned are 'very deep in the money' »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$16.71

-0.09 (-0.54%)

12:20
09/20/17
09/20
12:20
09/20/17
12:20
Options
Aggressive put buying in Canadian Solar »

Aggressive put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:18
09/20/17
09/20
12:18
09/20/17
12:18
Hot Stocks
ADP board has no shareholder orientation, Ackman says »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:17
09/20/17
09/20
12:17
09/20/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

, DLPH

Delphi

$100.97

0.07 (0.07%)

12:16
09/20/17
09/20
12:16
09/20/17
12:16
Periodicals
Delphi picks BlackBerry's QNX OS for self-driving platform, CNet reports »

Delphi (DLPH) has…

BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

DLPH

Delphi

$100.97

0.07 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

$NYE

NYSE Market Internals

12:16
09/20/17
09/20
12:16
09/20/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:15
09/20/17
09/20
12:15
09/20/17
12:15
Hot Stocks
Ackman says can work with ADP CEO after 'spoiled brat' comment »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
09/20/17
09/20
12:15
09/20/17
12:15
General news
FOMC balance sheet »

FOMC balance sheet: the…

ADP

ADP

$107.48

0.93 (0.87%)

12:14
09/20/17
09/20
12:14
09/20/17
12:14
Hot Stocks
Ackman says ADP margin opportunity closer to 1,200 basis points »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$309.39

5.98 (1.97%)

12:12
09/20/17
09/20
12:12
09/20/17
12:12
Hot Stocks
Ackman says Chipotle management doing 'all the right things' »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:11
09/20/17
09/20
12:11
09/20/17
12:11
Hot Stocks
ADP does not want shares held by Pershing supporters, Ackman says »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$921.81

6.81 (0.74%)

, GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

12:11
09/20/17
09/20
12:11
09/20/17
12:11
Periodicals
Google nears deal to buy assets from HTC, Bloomberg reports »

Google is nearing a deal…

GOOG

Alphabet

$921.81

6.81 (0.74%)

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

HMNY

Helios and Matheson

$5.70

2.22 (63.79%)

12:10
09/20/17
09/20
12:10
09/20/17
12:10
Periodicals
Helios and Matheson mentioned cautiously by TheStreetSweeper 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

, PAYX

Paychex

$58.07

-0.01 (-0.02%)

12:09
09/20/17
09/20
12:09
09/20/17
12:09
Hot Stocks
Ackman says 80% of ADP's issue is margins not at Paychex level »

Pershing Square's…

ADP

ADP

$107.48

0.93 (0.87%)

PAYX

Paychex

$58.07

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

ADP

ADP

$107.48

0.93 (0.87%)

12:08
09/20/17
09/20
12:08
09/20/17
12:08
Hot Stocks
Ackman says ADP products are not easy enough to use »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:06
09/20/17
09/20
12:06
09/20/17
12:06
Hot Stocks
Ackman says ADP overstates total shareholder returns under CEO »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUXTY

Luxottica

$57.52

0.06 (0.10%)

, ESLOY

Essilor

$63.35

-0.06 (-0.09%)

12:06
09/20/17
09/20
12:06
09/20/17
12:06
Downgrade
Luxottica, Essilor rating change  »

Luxottica downgraded to…

LUXTY

Luxottica

$57.52

0.06 (0.10%)

ESLOY

Essilor

$63.35

-0.06 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSEC

Prospect Capital

$6.72

0.07 (1.05%)

12:05
09/20/17
09/20
12:05
09/20/17
12:05
Options
Prospect Capital call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:01
09/20/17
09/20
12:01
09/20/17
12:01
Hot Stocks
Bill Ackman says ADP has 'massively underperformed potential' »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$158.73

0.06 (0.04%)

, ADBE

Adobe

$156.60

0.83 (0.53%)

12:00
09/20/17
09/20
12:00
09/20/17
12:00
General news
On The Fly: Top stock stories at midday »

The S&P and Dow were…

AAPL

Apple

$158.73

0.06 (0.04%)

ADBE

Adobe

$156.60

0.83 (0.53%)

FDX

FedEx

$221.74

5.74 (2.66%)

GIS

General Mills

$52.57

-2.81 (-5.07%)

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

IONS

Ionis Pharmaceuticals

$59.07

-0.5 (-0.84%)

CPRT

Copart

$32.54

-0.32 (-0.97%)

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

LB

L Brands

$37.50

-1.73 (-4.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 22

    Oct

AAPL

Apple

$158.73

0.06 (0.04%)

, JD

JD.com

$44.33

-0.41 (-0.92%)

11:55
09/20/17
09/20
11:55
09/20/17
11:55
Hot Stocks
Apple slides after reports of Watch connection issues, poor reviews »

Shares of Apple (AAPL)…

AAPL

Apple

$158.73

0.06 (0.04%)

JD

JD.com

$44.33

-0.41 (-0.92%)

CHL

China Mobile

$51.69

-0.23 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 22

    Oct

WDC

Western Digital

$89.92

0.74 (0.83%)

, TOSYY

Toshiba, also use TOSBF

$17.37

0.12 (0.70%)

11:44
09/20/17
09/20
11:44
09/20/17
11:44
Hot Stocks
Western Digital 'disappointed' in Toshiba proposed transfer of JV interests »

Western Digital (WDC)…

WDC

Western Digital

$89.92

0.74 (0.83%)

TOSYY

Toshiba, also use TOSBF

$17.37

0.12 (0.70%)

TOSBF

Toshiba, also use TOSYY

$2.89

0.01 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAYN

Layne Christensen

$12.32

0.15 (1.23%)

11:44
09/20/17
09/20
11:44
09/20/17
11:44
Hot Stocks
Layne Christensen making investments in energy midstream »

Says will be very…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.